Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Michael Grunkin

Michael Grunkin

CEO of Visiopharm, Denmark

Title: A business case for quantitative digital pathology

Biography

Biography: Michael Grunkin

Abstract

Pathologists all over the developed world are increasingly challenged both by the growing diagnostic volume and the complexity of cases to be read. These challenges are further amplified by shrinking budgets and the competitive pressures from new diagnostic modalities such as gene expression assays and next-generation sequencing. The widely published lack of data quality in terms of reproducibility, sensitivity and specificity of manual readings has probably contributed to generating a growing demand for new diagnostic modalities and probably also contributed to the growing pressure on budgets. Image analysis has the potential to impact significantly on data quality. In order to have such an impact, a number of essential technical solution components are required for mitigating several error sources on the journey from biopsy to diagnostic, prognostic or predictive tissue data. Solution requirements include: Correct and verifiable identification of invasive tumor cells, excluding stromal and pre-invasive cells, handling of tumor heterogeneity and identification of hot-spots, standardized quantification of sub-cellular biomarkers and gene probe assays in tumor cells and assessment of staining quality, which at least is possible for immunohistochemical markers. In studies, evidence is found suggesting that these four solution components have a profound impact on data quality. These studies further indicate that the combination of immunohistochemistry with image analysis controls are capable of yielding data of a quality and clinical utility which is at least comparable to alternative and competing methods but at a significantly lower cost. The underlying technical solution components and clinical study results are presented.